SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANRG -- Anergen -- new CEO big chance ?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tonyt who wrote (63)1/26/1998 2:29:00 PM
From: Larry Dreher  Read Replies (2) of 123
 
Murphy's last newsletter was still predicting a long term price of
$35.

He said that an interim analysis of its Phase II trial of AnervaX
showed the therapeutic vaccine was safe, well tolerated, and provided
persistent clinical benefit for symptoms of advanced rheumatoid
arthritis. More than 50% of patients receiving injections at six week
intervals had at least a 20% improvement, while 25% of patients in
the eight week group had 50% improvement or more.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News